The FDA has let down renal cancer patients with its Tivozanib decision. Strategies FDA’s flawed call on Aveo’s Tivozanib
Across the board the relative safety profile of Tivo stands out. Strategies How Aveo’s Tivo cancer drug stacks up against rivals